PER
Price sensitive
Percheron raises $2.3m to fully fund clinical trial in AML
Percheron Therapeutics Ltd
Percheron raises $2.3m to fund AML clinical trial
Key points
- Percheron completes $2.3m institutional placement
- Funds will fully fund clinical trial in AML
- Placement includes shares and options
- Shares to be issued at premium to market price
Full summary
Percheron Therapeutics Limited, an international biotechnology company, has completed a $2.3 million institutional placement to fully fund a clinical trial for acute myeloid leukemia (AML) in collaboration with Vanderbilt Health. The placement includes the issuance of new shares and options, with shares priced at a premium to the 15-day volume weighted average price. The funds will cover the costs of the trial and general working capital. The placement was strongly supported by existing and new investors, with shareholder approval sought at the 2026 AGM.
Sign in for more about this company, including guidance changes and other insights.
Sign in